FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia

FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia. MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/

Edison Pharmaceuticals today announced that the FDA granted Fast Track designation to EPI-743. The FDA has previously granted Orphan designation status to EPI-743 for the treatment of Friedreich's ataxia. Fast Track program provides a number of benefits to accelerate the development, FDA's Fast Track is designed to facilitate the development of drugs that have demonstrated potential to treat diseases that are serious, life threatening, and for which there is an unmet medical need.

FARA PRESS RELEASE